The aim this study was to evaluate imaging Wndings using position emission tomography (PET) in combination with computed tomography (CT) and 18F-Xuorodeoxyglucose ( 18 F-FDG) in sinonasal malignant melanoma (SNMM) of the head and neck in a retrospective analysis of a consecutive cohort of patients. 
Introduction
Mucosal malignant melanoma (MMM) is a very rare tumor counting for approximately 0.8-1.3% of all melanomas [1, 2] . The most common region for MMM is the head and neck, whereas other sites, such as the rectum and the anus, the urinary system, and the female genitalia may also be involved [1, 2] . The most prevalent sites of MMM in the head and neck are the nasal cavity, oral cavity, and the paranasal sinuses [1] . Sinonasal malignant melanoma (SNMM) accounts roughly for 4% of all head and neck melanomas and sinonasal malignancies alike [3] . Although the incidence of cutaneous melanoma is increasing, the incidence of MMM remains stable [1] .
Positron emission tomography (PET) with 18F-Xuorodeoxyglucose ( 18 F-FDG) is increasingly used for initial staging for head and neck malignancies. It is also an established tool for initial staging and follow-up imaging of cutaneous malignant melanomas [4] . In most centers, the standard imaging technique for MMM in the head and neck at initial staging is computed tomography (CT) or magnetic resonance imaging (MRI) if there is suspicion for skull base inWltration. The role of 18 F-FDG-PET in the management of MMM has been validated in a previous report by our institution [5] . Meanwhile, technology has evolved, and high-resolution multi-slice CT scanners are integrated in 18 F-FDG-PET-systems. The aim of this study was to elucidate imaging and the possible additional value of 18 F-FDG-PET/CT on therapeutic management of patients with MMM, particularly SNMM, when using it at initial staging or follow-up for locoregional or distant disease.
Materials and methods
We retrospectively reviewed the charts of all patients treated for MMM of the head and neck at the Department of Otolaryngology-Head and Neck Surgery, University Hospital Zurich, Switzerland . We revealed 10 patients, with sinonasal involvement only, examined by 18 F-FDG-PET/CT since the introduction of this technique at the Division of Nuclear Medicine, University Hospital Zurich, Switzerland, has been introduced in March 2001. If patients were referred to our institution with a CT or MRI scan done by the referring institution, these data were blindly re-evaluated by our double board certiWed radiologist and nuclear physician. In case of patients without previous imaging, the CT part from the fused 18 F-FDG-PET/CT was evaluated in a blind way without looking at the 18 F-FDG-PET part. All suspicious lesions detected by physical examination (endoscopy) and imaging (CT, MRI or 18 F-FDG-PET/CT) were further investigated by histological work-up which served as the standard of reference. The study was conducted in accordance with the local guidelines established by the ethics committee for retrospective evaluations. Each patient was followed by imaging using 18 F-FDG-PET/CT at 6-month intervals. 18 
F-FDG-PET/CT acquisition
For this study, we used a combined PET/CT system (Discovery STE or Discovery RX, GE Health Systems, Milwaukee, WI). This device integrates a PET scanner with a multi-slice helical CT (16 or 64 slices; slice thickness: 2.5 mm) and permits the acquisition of coregistered CT and PET images in the same session. Patients fasted for at least 4 h prior to scanning, which started approximately 60 min after the injection of a standard dose of approximately 350 MBq of 18 F-FDG. Patients were examined in the supine position. The CT scan was acquired during breath holding in the normal expiratory position. Immediately following the CT acquisition, the PET emission scan was acquired. The CT data were used for the attenuation correction and the images were reconstructed using a standard iterative algorithm (ordered subset expectation maximization (OSEM)) for 3D PET reconstruction. The acquired images were postprocessed with a dedicated software (AW workstation, GE Health Systems) providing multiplanar reformatted images of F-FDG-uptake. Attenuation-corrected 18 F-FDG-PET images were used for analysis. Lesions were interpreted as a malignancy if the uptake was higher than the uptake of the surrounding background tissue. It was a visual interpretation and not based on standardized uptake value (SUV) measurements. Furthermore, morphological Wndings of suspicious lesions provided by the low-dose CT part were also used for interpretation. 18 F-FDG-uptake in muscles, glands, brown fat or pulmonary inWltration were not interpreted as tumor or metastases. Four patients were initially examined after resection and therefore attribution of 18 F-FDG-uptake and histological Wnding was either equivocal or no more uptake was observed. Two patients received intravenous and oral contrast agent (Ultravist 300, GastrograWn, Bayer AG Switzerland) for obtaining either a diagnostic CT of the neck or of the whole body.
Semiquantitative analysis of 18 F-FDG-uptake in all suspicious lesions was performed by measuring the maximum standardized uptake value (SUV max).
Results

Clinical and histopathologic Wndings
The charts of ten consecutive patients (4 males, 6 females) were reviewed. The median age was 65 years (range, 49-82 years). At initial staging, no patient had clinical evidence of a primary melanoma elsewhere in the body. The MMM involved the nasal cavity and/or the adjacent ethmoidal and maxillary sinus in all cases (Table 1) . Most frequent symptoms at initial presentation were unilateral nasal hemorrhagic discharge, nasal obstruction, and facial pain. After clinical investigation including nasal endoscopy, a CT or MRI scan was acquired. In six patients (patient nos. 1, 3, 4, 5, 6, 7, Table 1 ), an additional 18 F-FDG-PET/CT scan for initial staging was obtained ( Fig. 1a-d) . In patient nos. 2, 8, 9, and 10 an additional 18 F-FDG-PET/CT after initial resection for re-staging was performed.
SNMM was conWrmed histologically and immunohistologically in all patients. Four tumors (nos. 1, 5, 8, 10; Table 1 ) showed the histologic pattern of an amelanotic melanoma. The primary tumor was surgically removed in all patients; postoperative percutaneous radiotherapy (intensity modulated radiotherapy, IMRT) was given to all but one patient (patient no. 9, Table 1 ) with a mean of 58 Gy. Two patients underwent adjuvant chemotherapy because of distant metastases detected during follow-up (patient nos. 1, 3; patient no. 1 was included in a study protocol receiving interferon alpha (IFNa; 3MU s.c., three times a week) plus Dacarbazine (DTIC 850 mg/m2 via intravenous (i.v) infusion on day 1 every 28 days during the Wrst 6 months; patient no. 3 was included in a diVerent study (SAKK 50/70) receiving Bevacizumab (Avastin ® 10 mg/kg via i.v. infusion every 2 week) and Temozolomid (Temodal ® 150 mg/m2 daily for 7 days every second week)). The median follow-up period was 17.5 months (range, 8-34 months). Five patients died as a result of locoregional recurrence and distant metastases ( Table 2) . Four Patients are alive with no evidence of disease, whereas one patient is known to have bone and pulmonary metastases (Table 2) . 18 
F-FDG-PET/CT Wndings versus other imaging Wndings
18 F-FDG-PET/CT was performed at the time of diagnosis before surgical resection in six patients, within 1 week after surgery (n = 4), and during follow-up (n = 24). A total of 34 18 F-FDG-PET/CT were analyzed for this study.
The follow-up examinations were performed between 5 and 33 months after diagnosis. Increased 18 F-FDG-uptake was observed in all patients with present tumors. All the 18 F-FDG-PET/CT Wndings with regard to the detection of the primary tumor were also detected by CT or MRI-scans and were well correlated in size. The contrast-enhanced (ce) CT part of the 18 F-FDG-PET/CT was able to approve the 18 F-FDG-PET Wndings. One cerebral metastasis was not detected either by 18 F-FDG-PET or by ceCT scanning and could only be found on MRI. Three suspicious lesions revealed by native CT (one osteolytic lesion in the spine; one small lesion in the lung; one enlarged lymph node in the mediastinum) showed none, or very little 18 F-FDG activity. During follow-up, these lesions turned out to be false-positive lesions as no growth or onset of symptoms could be shown.
Increased activity in soft tissue was located in brown fat tissue in one patient. Patient no. 10 showed repeatedly local 18 F-FDG activity at the site of resection (SUV 4.4-4.7). The fused CT did not approve a growing mass at this position and malignancy was Wnally ruled out by biopsy. 
Discussion
In general
Primary mucosal malignant melanoma (MMM) is a rare disease and occurs in older patients of both genders. Incidence of nasal cavity MMM was reported to be 0.018/10 [5] per year [6] . Only around 4% of all head and neck melanomas arise in the nasal cavity or adjacent paranasal sinuses [3] . The most common site of origin is the nasal septum, closely followed by the lateral nasal wall and the middle and inferior turbinates [3, 7] . Lymph node metastases are generally noted in about one-third of mucous membrane head and neck melanomas at initial presentation, implying a worse prognosis [1, 8] . The poorer prognosis for mucous membrane melanoma has been related to the tumor bulk (size), delay in diagnosis resulting from the non-speciWc nature of the presenting symptoms, diYcult visual examination, and technical inaccessibility of the primary tumor [9] .
Sinonasal malignant melanomas have, like cutaneous malignant melanomas, an increased glucose metabolism. The role of 18 F-FDG-PET in staging mucosal malignant melanomas of the head and neck has already been aYrmed [5] . 18 F-FDG-PET imaging is also known to be more sensitive and speciWc than CT for the detection of metastasis in melanoma patients [10] .
Advantages of 18 
F-FDG-PET/CT
At initial staging, all our patients showed increased 18 F-FDG uptake at the tumor site and could thus be easily identiWed. 18 F-FDG-PET-only imaging is lacking anatomical information. Complementary anatomical imaging is often required, especially for surgical therapy planning in this complex anatomical area. Coregistred 18 F-FDG-PET/CT has been available for a few years and provides such anatometabolic datasets in a single examination. 18 F-FDG-PET/CT has been found to be superior to CT alone and PET alone in staging and evaluation of therapy response in several oncological diseases including malignant melanoma [11] [12] [13] . 18 F-FDG-PET/CT as a functional and anatomical imaging method provides additional information for surgical therapy planning. Especially in the nasal cavity and paranasal sinuses, where anatomy is diYcult and diVerent vital structures are in close proximity, 18 F-FDG-PET/ CT appears to be superior to 18 F-FDG-PET alone. Particularly in recurrent tumors it seems essential to distinguish scar-tissue from melanoma masses and predicts the extent of aVection, which is not possible by CT alone. 18 F-FDG-PET without the additional information of the fused CT on the other hand is not able to give enough spatial resolution to perform exact surgical planning in the setting of the pre-operated nasal cavities and paranasal sinuses, where CT data add valuable information on fused images.
In a previous study by Department of OtolaryngologyHead and Neck Surgery, University Hospital Zurich, Switzerland, it could be shown that local tumor control in SNMM can be achieved in many cases and the majority of patients die from distant metastasis [7] . Hence, 18 F-FDG-PET/CT is in our opinion the imaging of choice during the follow-up period. 
Limitations of 18 F-FDG-PET/CT
A known limitation of 18 F-FDG-PET imaging is the identiWcation of brain metastases due to the high background metabolism as well as small melanoma metastases, where the spatial resolution of 18 F-FDG-PET/CT-imaging is not small enough [14] . We, too, did encounter these diYculties, as one cerebral metastasis was not seen during follow-up 18 F-FDG-PET/CT scans and was only identiWed by MRI. In a study by Gulec et al. [14] all of the 29 lesions larger than 1 cm showed 18 F-FDG uptake, whereas only two out of 15 lesions smaller than 1 cm were detected by 18 F-FDG-PET alone14. A theoretical three-dimensional spatial resolution of 4 mm can be achieved by modern 18 F-FDG-PET/CT scanners. However, due to motion and the tumor related uptake ratio, a spatial resolution of 6-8 mm can be expected realistically [15] . Veit-Haibach et al. [16] stated that 18 F-FDG-PET/CT show low sensitivities at initial staging of patients suVering from malignant cutaneous melanomas and therefore metabolic imaging should only be recommended as a Wrst-line diagnostic tool for selected melanoma patients in high-risk groups. Although none of our patients was found to have regional or distant metastasis upon Wrst imaging workup, all of the primary sites could be identiWed adequately. This is also due to late presentation of the oligosymptomatic patient in a late stadium with large tumor size, as stated above. As a rule, we believe it is advantageous performing the same follow-up imaging modality as that used for primary workup.
The cost-eVectiveness of 18 F-FDG-PET/CT DiVerent authors have described the cost-eVectiveness of 18 F-FDG PET/CT in staging head and neck squamous cell carcinoma (HNSCC) [17, 18] . The drawback of staging patients with 18 F-FDG PET/CT is the relatively high number of false-positive Wndings. Although many of the positive 18 F-FDG PET/CT Wndings will have an impact on the patient treatment, the costs of subsequent investigations and the burden caused to patients by additional investigations are considerable. Therefore, the indication for metabolic imaging should be handled reluctantly. A recent study showed 18 F-FDG PET/CT is the most eVective pretreatment screening method for distant metastases in HNSCC patients with risk factors [19] . It is our opinion, that in future, when integrated 18 F-FDG PET/CT and MRI scanners become routine, this will be the most cost-eVective imaging method for SNMM.
The role of CT Three 18 F-FDG-negative lesions (spine, lung, and mediastinum) detected and found to be suspicious by native CT were shown to be unsuspicious on 18 F-FDG-PET scanning. All of these Wndings were proven not to be malignant upon follow-up examination. These lesions represent false-positive Wndings on native CT scans; therefore, CT scanning should be ultimately performed ce, and, furthermore, 18 F-FDG negativity shows the potential to identify unreliable CT Wndings. On the other hand it can be challenging, especially in the head and neck area, to distinguish physiological or inXammatory uptake from malignant tissue which can be downsized by the ceCT part [20] .
As malignant mucosal melanoma is a very rare condition, it is diYcult to show signiWcant improvements in staging with 18 F-FDG-PET/CT because of the small number of patients. However, we know from previous reports on 18 F-FDG-PET/CT imaging that only few false-negative results are obtained, leading to a high negative predictive value, which is also supported by the current study. As modern 18 F-FDG-PET/CT scanners are providing a better resolution of the added CT information, one can also expect less false-positive Wndings. As shown, it is important to perform a ceCT part, which is not routine in many centers.
The role of MRI To evaluate dural or intracranial involvement, MRI seems to be indisputably the imaging modality of choice. However, the tumor's appearance is dependent on the amount of melanin found within. Melanotic tumors usually show hyperintensity on T1 images, whereas hypomelanotic or amelanotic melanomas may appear intermediate in signal intensities [21] [22] [23] . In our series 4/10 SNMM were amelanotic. In previous studies of mucosal melanoma, the frequency of amelanotic melanoma ranged from 25 to 42.9% [22] . All of the tumors in our series had increased 18 F-FDG uptake independent of their melanin contents which is in accordance with the literature.
Conclusion
In addition to the previously published experience concerning 18 F-FDG-PET imaging for the detection of MMM, the updated data presented in this study suggest that 18 F-FDG-PET/CT is superior to other imaging, e.g., CT or MRI scans, with its known limitations. Owing to the combined 18 F-FDG-PET and CT part, the visibility of SNMM is not solely dependent on 18 F-FDG activity anymore.
Therefore, if available, contrast-enhanced 18 F-FDG-PET/CT, in our opinion, is the adequate staging and restaging imaging modality to respond to the question of the expansion of the primary tumor, locoregional disease, or distant metastases.
If dural or intracranial involvement is clinically suspected, we believe that, additional MRI is required. However, it will never replace 18 F-FDG-PET/CT scanning as a staging modality unless MRI is fused with
